21
Apr
Lycotec quest to target the deadliest of crystals
Lycotec Ltd, a biotech company based in Cambridge UK, is raising funds to undertake a phase II clinical trial which would target cholesterol crystals. These crystals are one of the main causes of the rupture of atherosclerotic plaques. After breaking the cap of a vulnerable plaque, the crystals protrude into the lumen of coronary or […]
Read more
Categories
Recent posts
-
Lycotec presents at the American Heart Association’s Scientific Sessions4th November 2021
-
Lycotec CEO, Dr Ivan Petyaev to attend The Future Food-Tech Summit9th October 2019
Newsletter
Subscribe to our weekly newsletter now. Enter your email and name and click subscribe
Recent Tweets
-
@MelRichardsEh Most kits will be available on both, but not all. Some authors have chosen to sell their items exclu… https://t.co/eEvX43k7hb
3 hours ago -
We chatted with Katarina from #TheAunties about her career journey, the importance of mentorship, and the incredibl… https://t.co/3CLdpiweo8
6 hours ago -
@johancutych Hello, It appears you have successfully canceled your Envato Elements subscription. If you require fur… https://t.co/Mj2s9d7reB
8 hours ago
Recent Comments